FIT Biotech
Started in 1995, FIT Biotech concentrates on applications for its Gene Transfer Unit (GTU) technology. These applications include DNA vaccinations for HIV, tuberculosis, autoimmune diseases of various kinds. In addition, the technology applies to genetic adjuvants and cancer treatment. The company is listed on Nasdaq First North in Helsinki.
Started in 1995, FIT Biotech concentrates on applications for its Gene Transfer Unit (GTU) technology. These applications include DNA vaccinations for HIV, tuberculosis, autoimmune diseases of various kinds. In addition, the technology applies to genetic adjuvants and cancer treatment. The company is listed on Nasdaq First North in Helsinki.